signal
essenti
pathway
cell
cycl
control
dysregul
wnt
signal
pathway
viral
infect
report
studi
examin
effect
modul
signal
influenza
viru
infect
activ
pathway
increas
influenza
viru
mrna
viru
product
vitro
mous
lung
epitheli
cell
mrna
expresson
influenza
viru
gene
vivo
lung
mice
infect
influenza
viru
apuerto
howev
inhibit
signal
reduc
viru
titer
viral
gene
express
human
lung
epitheli
cell
viral
replic
primari
mous
alveolar
epitheli
cell
infect
differ
influenza
viru
strain
knockdown
also
reduc
viral
protein
express
viru
product
act
earli
stage
viru
replic
treatment
inhibit
express
viral
gene
vrna
crna
mrna
evalu
studi
intraperiton
administr
reduc
viral
load
improv
clinic
sign
partial
protect
mice
influenza
viru
infect
influenza
viru
singlestrand
negativesens
rna
viru
belong
orthomyxovirida
famili
genom
segment
encod
differ
protein
base
antigen
differ
nucleoprotein
np
matrix
protein
mp
influenza
virus
classifi
type
b
c
type
virus
subtyp
base
antigen
hemagglutinin
ha
neuraminidas
na
sixteen
ha
na
subtyp
recogn
influenza
virion
contain
negativesens
rna
vrna
synthesi
influenza
viru
rna
occur
three
step
vrna
transcrib
mrna
capsnatch
mechan
via
rnadepend
rna
polymeras
ii
intermedi
crna
synthes
vrna
iii
crna
copi
fulllength
negativesens
vrna
encapsul
new
progeni
viru
particl
gene
code
ha
mp
np
fig
mice
pretreat
infect
increas
mrna
level
ha
mp
np
lung
also
observ
fig
result
indic
treatment
increas
influenza
viru
replic
morev
influenza
viru
infect
cell
increas
activ
signal
topflash
report
although
effect
fig
suggest
influenza
viru
activ
signal
next
examin
effect
inhibit
signal
influenza
viru
product
small
molecul
inhibit
signal
prevent
bind
leftcf
transcript
factor
use
studi
use
signal
topflash
report
assay
first
valid
inhibit
signal
fig
human
alveolar
epitheli
cell
treat
h
infect
influenza
viru
moi
vari
amount
time
infecti
viru
particl
releas
medium
quantifi
use
tcid
assay
viru
titer
cell
significantli
reduc
h
postinfect
hpi
compar
control
cell
fig
similar
result
observ
viru
fig
effect
due
toxic
effect
cell
viabil
fig
also
test
abil
inhibit
viru
replic
variou
influenza
viru
strain
use
influenza
viru
sensor
report
assay
expect
reduc
replic
assay
also
inhibit
replic
clinic
isol
fig
result
indic
antivir
activ
multipl
strain
influenza
viru
confirm
effect
signal
influenza
viru
infect
inhibit
signal
knockdown
previous
shown
twenti
four
h
post
transfect
cell
treat
concm
presenc
absenc
h
topflash
firefli
luciferas
activ
normal
prltk
renilla
luciferas
activ
p
n
oneway
anova
follow
tukey
test
b
c
cell
treat
vehicl
control
h
infect
influenza
viru
b
c
moi
cell
cultur
medium
collect
variou
time
postinfect
viral
titer
determin
tcid
assay
cell
treat
vehicl
control
variou
time
cell
viabil
measur
use
celltit
glo
kit
promega
result
independ
experi
display
mean
se
p
vs
vehicl
control
p
vs
vehicl
control
correspond
time
point
twoway
anova
post
hoc
tukey
e
cell
cotrasnfect
influenza
viru
sensor
report
nputrluc
prltk
vector
knockdown
use
adenovir
shrna
inhibit
transdifferentitaion
rat
alveolar
epitheli
type
ii
cell
type
cell
infect
rat
lung
epitheli
cell
adenovir
shrna
result
mark
reduct
express
fig
reduct
protein
level
significantli
inhibit
influenza
viral
protein
np
express
fig
progenc
influenza
viru
product
fig
influenza
viru
undergo
sever
step
life
cycl
host
cell
period
entri
bud
determin
stage
viral
life
cycl
inhibit
ad
inhibitor
variou
time
infect
determin
viru
titer
medium
hpi
ad
h
hpi
viru
titer
decreas
fig
howev
effect
viru
titer
ad
hpi
result
indic
act
earli
stage
viral
infect
viral
gene
transcript
examin
effect
express
level
variou
influenza
viral
rna
cell
treat
h
prior
infect
infect
influenza
viru
moi
h
crna
vrna
mrna
measur
realtim
pcr
ribavirin
inhibit
influenza
viru
rna
synthesi
inhibit
polymeras
complex
use
posit
control
experi
similar
ribavirin
markedli
reduc
level
vrna
crna
mrna
segment
viral
rna
includ
polymeras
basic
polymeras
basic
polymeras
acid
pa
ha
np
na
mp
nonstructur
protein
ns
fig
effect
dose
interferon
ifn
first
line
defens
influenza
viru
influenza
viru
infect
induc
ifn
product
requir
mount
proper
antivir
respons
design
two
set
experi
test
whether
ifn
involv
antivir
activ
first
examin
effect
influenza
viru
ifn
gene
express
induc
mrna
express
cell
howev
effect
induct
fig
second
repeat
experi
describ
fig
use
vero
cell
defici
ifn
product
reduc
level
vrna
crna
mrna
np
gene
vero
cell
similar
effect
cell
fig
result
suggest
ifn
may
play
major
role
antivir
activ
alveolar
epitheli
cell
aec
one
primari
target
influenza
viru
examin
whether
also
reduc
influenza
viru
infect
primari
aec
aec
ii
isol
mice
cultur
day
allow
differenti
aec
day
cell
show
uniform
stain
aec
marker
fig
treat
cell
vehicl
infect
influenza
viru
moi
h
measur
viru
titer
medium
na
mrna
cell
found
reduc
viru
titer
fig
na
mrna
level
fig
cell
result
indic
also
effect
repress
influenza
viru
product
primari
aec
evalu
whether
caus
toxic
mice
test
antivir
activ
vivo
mice
treat
dose
mgkg
vehicl
control
daili
day
via
intraperiton
rout
sacrif
day
major
organ
includ
liver
lung
heart
kidney
stomach
small
intestin
eye
brain
process
histopatholog
analysi
microscop
lesion
score
pathologist
major
organ
toxic
treatment
observ
either
dose
test
whether
protect
mice
influenza
viru
infect
perform
surviv
studi
use
lethal
dose
influenza
viru
pfumous
twentyf
mice
treat
mgkg
bodi
weight
vehicl
dmso
one
day
prior
infect
daili
thereaft
day
infect
dose
chosen
base
publish
report
tumor
studi
anim
surviv
monitor
daili
iav
infect
total
mice
vehicl
control
mice
surviv
mice
die
reach
bodi
weight
loss
mice
euthan
accord
criteria
euthanasia
though
mice
die
within
day
infect
mice
exhibit
slightli
less
bodi
weight
loss
day
fig
slight
improv
surviv
time
fig
challeng
mice
subleth
dose
pfumous
examin
result
viru
load
lung
patholog
bodi
weight
anim
survial
observ
day
total
mice
mortal
observ
either
control
group
also
differ
bodi
weight
loss
control
group
significantli
reduc
viru
titer
lung
tissu
day
postinfect
fig
mice
show
significantli
lower
clinic
score
control
mice
day
postinfect
fig
mice
treat
display
decreas
wettodri
ratio
indic
extravascular
edema
lung
day
infect
fig
observ
differ
total
protein
number
inflammatori
cell
macrophag
neutrophil
lymphocyt
ldh
activ
bal
control
group
fig
suggest
improv
alveolar
leakag
cell
injuri
inflamm
h
e
stain
reveal
day
postinfect
equivoc
reduc
epitheli
degener
andor
necrosi
major
airway
compar
vehicl
control
tabl
day
postinfect
decreas
attenu
epithelium
loss
cilia
lung
anim
receiv
treatment
subtl
decreas
sever
lung
lesion
alveolar
histiocyt
infiltr
neutrophil
histiocyt
infiltr
major
airway
treatment
group
day
postinfect
compar
control
group
fig
tabl
studi
found
activ
enhanc
influenza
viru
replic
inhibit
pathway
decreas
influenza
viru
transcript
product
new
viru
act
viral
rna
synthesi
also
show
partial
protect
effect
mous
model
influenza
viru
infect
variou
host
signal
pathway
alter
influenza
viru
infect
thu
pathway
might
provid
potenti
therapeut
target
cellular
signal
pathway
nuclear
factor
kappalightchainenhanc
activ
b
cell
signal
mitogenactiv
protein
kinas
mapk
pathway
phosphoinositid
pathway
protein
kinas
rnaactiv
pkr
signal
tolllik
receptorretino
acid
induc
gene
tlrrigi
signal
cascad
report
play
role
variou
stage
influenza
viru
replic
cycl
signal
essenti
host
innat
immun
respons
activ
influenza
viru
infect
activ
signal
increas
influenza
viru
product
induc
proapoptot
factor
influenza
viru
also
activ
mapk
pathway
block
signal
pathway
inhibit
viral
replic
impair
viral
ribonucleoprotein
traffick
anoth
pathway
pathway
activ
influenza
viru
via
interact
nonstructur
protein
influenza
viru
infect
robust
activ
ifn
respons
occur
turn
activ
pkr
signal
pathway
howev
influenza
viru
also
counteract
activ
pkr
pathway
bind
doublestrand
rna
therebi
prevent
translat
arrest
pattern
recognit
receptor
tlr
rigi
like
receptor
rlr
recogn
viral
rna
induc
antivir
immun
respons
influenza
viru
also
evolv
mechan
counteract
induct
antivir
respons
exampl
inhibit
rigi
activ
ifn
product
bind
tripartit
motifcontain
protein
ubiquitin
ligas
requir
rigi
activ
current
studi
demonstr
activ
signal
enhanc
influenza
viru
replic
show
enhanc
viral
gene
express
limit
studi
effect
signal
influenza
viru
infect
yeast
twohybrid
screen
reveal
viral
protein
includ
np
pa
interact
wnt
signal
compon
use
rnai
approach
silenc
variou
compon
signal
affect
replic
howev
result
studi
difficult
interpret
delet
gene
either
posit
neg
effect
replic
howev
delet
reduc
viru
replic
consist
inhibitor
studi
anoth
studi
show
addit
overexpress
inhibit
influenza
viru
replic
contrast
observ
actual
enhanc
viral
replic
knockdown
reduc
influenza
viru
replic
discrep
like
due
differ
strain
use
mechan
signal
regul
influenza
viru
infect
unclear
sever
possibl
modul
immun
respons
signal
pathway
known
modul
inflammatori
immun
respons
via
interact
pathway
howev
effect
signal
virusinduc
immun
respons
remain
controversi
instanc
hillesheim
et
al
shown
activ
wnt
signal
pathway
overexpress
support
iavinduc
transcript
gene
cellular
innat
immun
respons
isg
howev
recent
studi
demonstr
induct
wnt
ligand
negativestrand
rna
viru
infect
suppress
type
ifn
respons
current
studi
support
role
type
ifn
respons
context
inhibitori
effect
inhibitor
influenza
viru
infect
via
enhanc
ifn
respons
fig
ii
modul
cell
cycl
prolifer
signal
promot
transit
transcript
upregul
cell
cycl
relat
target
gene
cmyc
cyclin
prolif
statu
promot
wnt
signal
may
provid
abund
resourc
viru
cap
snatch
shown
anoth
neg
strand
rna
viru
rift
valley
fever
viru
select
snatch
cell
cyclerel
cellular
mrna
allow
viral
protein
traffic
cytoplasm
nucleu
activ
instanc
cawood
et
al
demonstr
nucleocapsid
protein
coronaviru
mobil
prolif
cell
local
nucleolu
cell
cycledepend
manner
also
show
maintain
abil
inhibit
influenza
viru
replic
ifndefici
vero
cell
effect
influenza
virusinduc
type
ifn
gene
express
cell
differ
effect
ifn
respons
viru
infect
report
wnt
ligand
neg
regul
ifn
respons
sendai
viru
infect
delet
posit
regul
ifn
respons
contrast
increas
ifn
respons
absenc
protein
main
protein
influenza
viru
use
repress
host
ifn
respons
transfect
plasmid
cell
also
induc
interferonsensit
respons
element
isr
gene
report
cell
treat
cellular
viral
rna
xenograft
model
cell
sever
combin
immunodefici
scid
mice
treatment
shown
significantli
reduc
tumor
volum
mous
ewe
sarcoma
vivo
also
inhibit
howev
pauciti
literatur
toxic
anim
toxic
studi
mice
reveal
major
toxic
organ
includ
lung
liver
kidney
brain
heart
eye
subleth
influenza
infect
mous
model
mice
show
less
sever
clinic
sign
correl
observ
mice
lower
viru
load
day
post
infect
viru
load
less
group
day
post
infect
howev
reach
signific
level
although
believ
due
lower
titer
day
anim
variat
rule
possibl
eexert
secondari
effect
anim
influenza
viru
infect
caus
acut
lung
injuri
includ
damag
endotheli
epitheli
cell
disrupt
endotheli
alveolar
barrier
leakag
protein
alveolar
space
inflammatori
cell
infiltr
howev
appear
effect
paramet
lung
injuri
inflamm
reduct
lung
edema
lethal
influenza
infect
observ
slightli
less
weight
loss
slightli
delay
mortal
mice
end
point
could
use
improv
efficaci
use
medicin
chemistri
formul
reduc
viru
load
improv
clinic
sign
combin
therapi
drug
reduc
lung
injuri
increas
efficaci
present
studi
provid
evid
activ
signal
increas
influenza
viru
gene
express
viru
product
inhibit
signal
limit
influenza
viru
product
reduc
viral
rna
synthesi
mous
alveolar
epitheli
cell
type
ii
aec
ii
isol
male
mice
week
age
previous
describ
experi
carri
approv
oklahoma
state
univers
institut
anim
care
use
committe
accord
public
health
servic
ph
polici
human
care
use
laboratori
anim
mice
anesthet
ketamin
xylazin
abdomin
caviti
open
anim
exsanguin
interrupt
abdomin
aorta
lung
cannul
cathet
via
trachea
lung
perfus
solut
ii
mm
hepe
ph
nacl
glucos
mm
kcl
mm
mgso
mm
cacl
mgml
streptomycin
sulfat
mgml
penicillin
g
mm
na
hpo
mm
nah
po
follow
instil
ml
solut
ml
solut
ii
plu
ml
dispas
stock
caseinolyt
unitsml
trachea
three
lung
isol
pool
beaker
contain
approxim
ml
solut
incub
min
releas
aec
incub
lung
chop
digest
addit
dnase
solut
ml
min
intermitt
shake
digest
lung
filter
sequenti
gaug
nylon
mesh
filtrat
centrifug
g
min
cell
pellet
resuspend
dmem
incub
petri
dish
coat
mous
igg
per
dish
h
cell
centrifug
g
min
resuspend
dmem
contain
fb
yield
approxim
cell
per
mice
cell
viabil
stabl
cell
line
express
solubl
murin
control
murin
lcell
line
atcc
maintain
dmem
supplement
fb
lglutamin
mgml
invitrogen
carlsbad
ca
usa
obtain
control
con
condit
medium
cm
cell
cultur
fresh
growth
medium
dmem
fb
without
day
fresh
medium
addit
day
cultur
media
mix
steril
filter
store
use
concm
prepar
concentr
ml
cm
ml
use
ultrafiltr
kit
millipor
billerica
usa
stock
strain
influenza
viru
well
clinic
isol
propag
allanto
caviti
specificpathogenfre
embryon
chicken
egg
charl
river
laboratori
usa
allanto
fluid
harvest
centrifug
g
min
store
viru
titer
determin
tissu
cultur
infect
dose
tcid
assay
briefli
mdck
cell
seed
plate
densiti
cell
per
well
next
day
cell
wash
twice
serumfre
medium
seri
tenfold
dilut
stock
allanto
fluid
cell
cultur
supernat
rang
prepar
serumfre
medium
chloromethyl
ketonetr
trypsin
tpcktrypsin
cell
infect
dilut
viru
stock
triplic
h
cultur
cell
analyz
cytopath
effect
cpe
tcid
calcul
use
reedmuench
method
primari
aec
ii
cell
cultur
type
collagenco
plate
cell
well
cover
slip
day
cell
seed
densiti
cellswel
plate
h
cell
wash
twice
serumfre
medium
cell
infect
viru
serumfre
medium
contain
tpcktrypsin
desir
multipl
infect
moi
co
incub
h
cell
wash
pb
complet
medium
contain
fb
ps
ad
h
postinfect
total
viral
mrna
cell
viru
titer
medium
determin
rat
lung
epitheli
cell
atcc
seed
plate
x
well
cultur
medium
contain
fb
ps
h
cell
infect
adenoviru
contain
shrna
control
vector
moi
previous
describ
h
infect
adenoviru
remov
cultur
medium
ad
cultur
anoth
h
cell
wash
serumfre
media
infect
moi
h
serumfre
medium
contain
tpcktrypsin
influenza
viru
remov
cell
cultur
serumfre
medium
contain
bsa
tpcktrypsin
h
cell
lyse
western
blot
media
use
plagu
assay
primari
antibodi
use
includ
rabbit
immunofluoresc
alveolar
epitheli
cell
fix
icecold
paraformaldehyd
min
wash
pb
cell
permeab
triton
min
wash
block
goat
serum
incub
hamster
antibodi
dilut
development
studi
hybridoma
bank
univers
iowa
overnight
follow
incub
alexa
fluor
antihamst
secondari
antibodi
life
technolog
grand
island
ny
usa
dilut
final
cell
stain
dihydrochlorid
dapi
coverslip
mount
glass
slide
imag
tocri
bioscienc
minneapoli
mn
usa
stock
solut
mm
prepar
dimethyl
sulfoxid
dmso
dilut
yield
desir
concentr
appropri
medium
differ
cell
type
dmso
use
vehicl
control
cell
viabil
assay
cell
seed
plate
densiti
cellswel
next
day
cell
treat
cell
collect
variou
time
cell
viabil
determin
use
luminesc
cell
viabil
assay
promega
madison
wi
usa
assay
measur
rel
number
viabl
cell
base
metabol
activ
cell
quantifi
cellular
atp
content
luminesc
signal
total
rna
extract
use
tri
reagent
molecular
research
center
cincinnati
oh
usa
treat
dnase
ambion
grand
island
ny
usa
host
mrna
rna
reversetranscrib
cdna
use
oligo
dt
random
primer
dehydrogenas
gapdh
use
housekeep
gene
control
variou
type
viral
rna
quantifi
describ
one
microgram
rna
reversetranscrib
use
strandand
sensespecif
primer
vrna
crna
mrna
oligo
dt
gapdhspecif
primer
ad
revers
transcript
reaction
primer
use
studi
list
tabl
cdna
dilut
nucleasefre
water
realtim
pcr
carri
reaction
mixtur
contain
specif
primer
sybr
green
dna
dye
anaspec
fremont
ca
usa
pcr
perform
fast
realtim
pcr
system
appli
biosystem
foster
citi
ca
usa
cycl
condit
min
cycl
viral
rna
level
express
threshold
cycl
c
valu
normal
gapdh
level
use
method
forward
anim
procedur
approv
institut
anim
care
use
committe
iacuc
oklahoma
state
univers
eightweekold
femal
mice
jackson
laboratori
bar
harbor
use
studi
anim
hous
environment
condit
met
applic
standard
anim
anesthet
intraperiton
inject
ketamin
mgkg
xylazin
mgkg
mice
infect
intranas
plaqu
form
unit
pfu
lethal
challeng
pfu
subleth
challeng
influenza
viru
volum
mice
receiv
intraperiton
inject
mgkg
bodi
weight
dmso
vehicl
control
volum
one
day
prior
viru
infect
daili
day
day
indic
mice
monitor
clinic
sign
arch
back
huddl
ruffl
fur
bodi
weight
loss
monitor
daili
anim
health
behavior
frequent
observ
anim
caretak
mice
lost
origin
bodi
weight
euthan
inject
ketamin
mgkg
xylazin
mgkg
follow
cervic
disloc
subleth
studi
clinic
sign
score
previous
describ
normal
ruffl
fur
inact
hunch
back
moribund
mice
euthan
day
day
infect
left
lung
anim
fix
neutral
buffer
formalin
thermo
scientif
west
palm
beach
fl
usa
right
lung
snapfrozen
liquid
nitrogen
use
rna
protein
viru
titer
determin
determin
viru
titer
lung
tissu
right
cranial
lung
lobe
infect
mice
homogen
wv
phosphatebuff
salin
pb
use
tcid
assay
separ
experi
right
lung
anim
use
collect
broncheoalveolar
lavag
bal
left
lung
use
determin
wettodri
ratio
right
lung
lavag
twice
icecold
pb
approxim
appli
volum
recov
bal
cell
centrifug
resuspend
cytospin
slide
slide
stain
dip
quick
stain
jorvet
loveland
co
usa
differenti
cell
count
perform
use
cell
per
sampl
bal
fluid
frozen
use
lavag
right
lung
lobe
mous
group
use
ldh
assay
total
protein
measur
fiftymicrolit
aliquot
use
measur
activ
ldh
monitor
reduct
nicotinamid
adenin
dinucleotid
nm
presenc
lactat
use
thermo
scientif
rockford
il
usa
ldh
assay
kit
total
protein
bal
fluid
estim
modifi
bradford
assay
biorad
hercul
ca
usa
accord
manufactur
instruct
remaind
fluid
frozen
process
anim
euthan
exsanguin
abdomin
aorta
xylazin
ketamin
anesthesia
follow
approv
iacuc
protocol
formalineperfus
lung
embed
paraffin
wax
section
thick
cut
stain
hematoxylin
eosin
h
e
histopatholog
lesion
score
boardcertifi
pathologist
describ
minim
damag
alveolar
structur
mild
moder
markedsever
damag
lung
tissu
cell
cotransfect
topflash
report
plasmid
ng
contain
three
copi
lef
bind
site
upstream
thiamin
kinas
tk
minim
promot
firefli
luciferas
gene
emd
millipor
billerica
usa
prltk
vector
ng
normal
twenti
four
h
post
transfect
cell
infect
moi
left
uninfect
firefli
renilla
luciferas
activ
measur
use
dualluciferas
report
assay
kit
promega
madison
wi
usa
detect
influenza
viru
replic
construct
influenza
luciferas
report
vector
encod
firefli
luciferas
control
np
utr
influenza
awsn
accord
previou
report
firefli
luciferas
gene
insert
rna
polymeras
express
vector
kind
gift
dr
yoshi
kawaoka
univers
wisconsin
bsmb
site
nputrluc
cell
cotrasnfect
viru
sensor
nputrluc
ng
prltk
vector
ng
data
least
three
independ
experi
analyz
result
statist
analyz
use
student
ttest
oneway
twoway
anova
follow
post
hoc
tukey
sidak
test
use
graph
pad
prism
version
p
valu
consid
signific
support
inform
file
plosonehumanendpointschecklistdoc
docx
